Effects of glucagon-like peptide-1 receptor agonists on radical cystectomy outcomes: a pilot study
Canadian Journal of Urology · 2026 · 1-10
DOI: 10.32604/cju.2026.079766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Urology, 2026. Verfasst von Craig Cronin und 7 weiteren Autor:innen.
Abstract (Originalsprache)
. Effects of glucagon-like peptide-1 receptor agonists on radical cystectomy outcomes: a pilot study. Can J Urol 2026.
Background
Radical cystectomy with urinary diversion is associated with substantial postoperative morbidity, including kidney-related complications, yet the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on these outcomes remain understudied. The objective of this pilot study was to determine the association between GLP-1RA use within one year of surgery and postoperative adverse events following radical cystectomy utilizing the TriNetX database.
Methods
Using the TriNetX national claims database, we identified adults undergoing radical cystectomy for bladder cancer. Patients with documented GLP-1RA use within one year prior to surgery were 1:1 matched to controls without GLP-1RA exposure based on demographics (age, sex, race, body mass index) and comorbidities (diabetes mellitus, hypertension, hyperlipidemia, chronic kidney disease, tobacco dependence). We compared various 30-day and 90-day postoperative adverse events, readmission, and kidney function outcomes, including major adverse kidney events (MAKE), acute kidney injury (AKI), and metabolic acidosis, between groups using logistic regression analysis.
Results
Among 23,081 patients undergoing radical cystectomy, 293 had documented preoperative GLP-1RA use and were matched to 293 controls. No significant differences were observed in 30-or 90-day rates of ileus or obstruction (p 30-day = 0.90, p 90-day = 0.55), infections (p 30-day = 0.85, p 90-day = 0.55), respiratory failure (p 30-day = 0.99, p 90-day = 0.88), readmissions (p 30-day = 0.59, p 90-day = 0.50), or emergency department visits (p 30-day = 0.19, p 90-day = 0.08). Renal function outcomes, including the risk of MAKE (p = 0.53) and AKI (p = 0.06), were similar between groups at 90-day. GLP-1RA users were at significantly higher odds of exhibiting metabolic acidosis (OR 1.7, 95% CI 1.2–2.6, p = 0.01).
Conclusions
Documented preoperative GLP-1RA prescription was not associated with increased perioperative morbidity following radical cystectomy, though claims-based data preclude a definitive conclusion regarding pharmacologic safety. The potential increased risk of metabolic acidosis in this database study warrants validation with prospective clinical studies.
Zitieren
APA
Cronin, C., Weitzner, A. S., Lokeshwar, S. D., Korn, P., Cheaib, J. G., Garman, T. S., Patel, S. H., & Singla, N. (2026). Effects of glucagon-like peptide-1 receptor agonists on radical cystectomy outcomes: a pilot study. Canadian Journal of Urology, 0(0), 1-10. https://doi.org/10.32604/cju.2026.079766
Vancouver
Cronin C, Weitzner AS, Lokeshwar SD, Korn P, Cheaib JG, Garman TS, et al. Effects of glucagon-like peptide-1 receptor agonists on radical cystectomy outcomes: a pilot study. Canadian Journal of Urology. 2026;0(0):1-10. doi:10.32604/cju.2026.079766
BibTeX
@article{Cronin2026,
author = {Cronin, Craig and Weitzner, Aidan S. and Lokeshwar, Soum D. and Korn, Philipp and Cheaib, Joseph G. and Garman, Tyler S. and Patel, Sunil H. and Singla, Nirmish},
title = {Effects of glucagon-like peptide-1 receptor agonists on radical cystectomy outcomes: a pilot study},
journal = {Canadian Journal of Urology},
year = {2026},
volume = {0},
number = {0},
pages = {1--10},
doi = {10.32604/cju.2026.079766}
}
EUVIMED